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Abstract
Congenital heart disease (CHD) is the most common major birth defect in children,
affecting nearly 3% of children and is the leading cause of infant mortality [1]. Heterotaxy (Htx)
is a disorder of left-right (LR) patterning, in which organs, including the heart, are mispatterned
relative to the LR axis. Htx is associated with severe forms of CHD, but its genetic causes
remain largely undefined [2]. Exome sequencing studies of large patient cohorts have recently
revealed hundreds of CHD/Htx candidate disease genes, which now need to be validated in
experimental systems for causality in order to better understand the causes and biological
mechanisms of CHD/Htx. Recently, the membrane-bound transcription factor MYRF has
emerged as a candidate CHD/Htx gene in 14 patients with 13 unique variants. This is intriguing,
as MYRF has an established role in the generation and maintenance of myelin in the central
nervous system, but no known functional role in LR patterning or cardiac development. Here,
we show that myrf is essential for LR patterning and gastrulation in Xenopus. Our data suggests
both the LR patterning and delayed gastrulation phenotype are due to an upregulation of Nodal
signaling indicating that myrf normally suppresses nodal. Searching for candidate genes
downstream of MYRF, we identified the proprotein convertase FURIN as a potential target. Our
results demonstrate that myrf suppresses furin transcription, which affects Nodal signaling via
furin’s role in nodal ligand processing. Together, we provide a plausible mechanism for LR
patterning defects and congenital heart disease in patients with MYRF variants. In doing so, we
hope to better elucidate the molecular mechanisms of cardiac development and LR patterning
and understand how these variants lead to disease in order to eventually provide genetic
counseling, prognosis and therapeutics for patients with this rare disease.
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Introduction
1.1 Congenital Heart Disease
CHD, defined as a gross structural abnormalities of the heart or great vessels, is the
most common major birth defect, with an estimated prevalence of 8 cases per 1000 live births
[3]. Variations in prevalence by geographic area exist and may be due to differences in
diagnostic ability and increased genetic risk due to consanguinity [4] With a high morbidity and
mortality, patients with CHD often require early surgical care within the first year of life in order
to survive [5]. Furthermore, CHD takes a financial toll, as total expenditure for care of patients
with CHD in the United States exceeded 6.1 billion in 2013 [6].
While once considered a death sentence, mortality from CHD has decreased over the
past few decades due to improved medical and surgical care, with a 10 year survival over 80%
[5] [7]. This has led to an evolution of care among an adult population with CHD, including late
complications such as arrhythmias, heart failure, endocarditis and pulmonary hypertension in
this patient population [8]. Furthermore, CHD has been associated with neurodevelopmental
disabilities (NDD), with the prevalence of NDD in patients with CHD ranging from 10-50% based
on the severity of CHD and the need for surgery during infancy [9]. However, despite the
progress made, CHD remains the leading cause of mortality from birth defects in the developed
world [1]. Therefore, it is vital that continued research help elucidate the mechanism of CHD and
discover new treatments.
1.2 Heterotaxy
Heterotaxy (Htx) is a disorder of LR patterning, in which organs, including the heart, are
mispatterned relative to the LR axis. Positioning along the LR axis can be divided into three
broad categories: situs solitus, situs inversus, and situs ambiguous (Figure 1). Situs solitus
occurs when the LR axis is developed appropriately, with proper alignment of organs.
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Conversely, situs inversus refers to organs arranged in mirror image across the LR axis. Situs
inversus can be associated with syndromes, such as Kartagener’s Syndrome, where ciliary
defects lead to not only LR patterning defects, but also adverse effects in the respiratory
system, renal system, and reproductive system [10]. However, patients with situs inversus can
also lead normal lives, with no major intra-organ defects. This is as opposed to situs ambiguous,
where there is no clear arrangement of organs along the LR axis. Htx falls under this category,
and examples of situs ambiguous are shown in Figure 1 including right isomerism, where there
are two “right” sides of the body, and left isomerism, where there are two “left” sides of the body.

Figure 1: A schematic representation of possible organ placement on the LR axis. Situs solitus is shown
on the left, where organs are placed in their appropriate positions. The image on the right represents situs
inversus, where organs are placed in its mirror image. In between are two examples of abnormal organ
placement, which is considered as part of the heterotaxy spectrum. Image from Fakhro et al, 2011.

The heart is highly susceptible to perturbations in LR patterning because the organ is
structurally and functionally asymmetric. That is, structurally, the heart is positioned on the left
and tilted such that the right ventricle is the most anterior structure and the left atrium is the
most posterior portion. Functionally, blood enters the right side of the heart to be pumped to the
lung for gas-exchange, and then returns to the left side of the heart, where higher pressures
allow it to be pumped to the systemic circulation. Therefore, although htx is a rare syndrome,
affecting 1 out of 10,000 live births [11], htx contributes to 3% of all CHD cases, the majority of
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which are extremely severe and result in high mortality rates [12]. An additional unknown
number of cases leading to stillbirths and miscarriages are also present, further emphasizing the
need for more knowledge.
1.3 Etiology and Genetics of CHD/Htx
Studies suggest that 20-30% of CHD cases are due to a genetic or environmental
cause, leaving the remaining 70% to have no known etiology [13]. The task of identifying
genetic causes and understanding their mechanism in CHD/Htx has been difficult for many
reasons. Firstly, htx can occur either as a syndrome, where multiple organs are affected, or the
LR patterning abnormality can occur in an isolated setting. In both cases, htx can result in a
broad range of structural cardiac abnormalities, making diagnosis very difficult and limiting the
ability to identify candidate genes [12]. Htx is also a rare disease that occurs sporadically, and
many cases have variable expressivity and incomplete penetrance. Therefore, it is difficult to
accurately track family pedigrees. This, in addition to the existence of de novo gene variants,
complicates our ability to gain an understanding of CHD/Htx pathogenesis without large scale
patient studies.
The earliest identified genetic cause of CHD was chromosomal aneuploidies, with the
most well-known example being Trisomy 21. 35-50% of patients with Down’s Syndrome are
diagnosed with CHD [5]. Again, due to the large range of genes affected and phenotypes seen
with aneuploidies, it is unfortunately difficult to identify causal genes and pinpoint an exact
molecular mechanism. However, advances in genotyping microarrays has allowed us to identify
copy number variations (CNV). CNVs, which are gene deletions or duplications, can vary in size
from involving a single gene to disrupting millions of base pairs, and CNVs underlie many wellknown clinical syndromes with CHD phenotypes, such as DiGeorge Syndrome [5]. Like
aneuploidies, CNVs that span multiple genes provide limited information for analysis without
functional analysis in animal models. However, a 2011 study found that small CNVs were highly
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represented in patients with htx [14]. This study evaluated 262 htx subjects and 991 controls to
identify candidate htx genes, and further analysis based from this study has led to a better
understanding of how diverse genes, such as the glycosylation transferase galnt11 and the
nuclear pore protein nup188 can lead to htx [15] [16]
More recently, whole exome and whole genome sequencing technologies have allowed
researchers to identify de novo mutations using genomic data from CHD patients and their
parents. A large-scale exome sequencing study showed that 10% of CHD is due to de novo
mutations, and this number increases to 20% in patients with CHD associated with extracardiac
conditions or NDD [17]. This same study was the first to identify myrf as a candidate CHD/Htx
gene in a patient with abnormal left-sided cardiac and aortic arch development. Since then, this
gene has been identified in multiple CHD/Htx patients, making it crucial to learn its mechanism
of action.
1.4 Myelin Regulatory Factor (MYRF)
As the name suggests, MYRF is a membrane-bound transcription factor important for
oligodendrocyte differentiation and regulating myelination in the central nervous system such
that MYRF knockout in mice oligodendrocytes leads to severe myelination defects and loss of
myelin gene expression [18]. Furthermore, ChIP-seq data generated in rat oligodendrocyte cells
show an enrichment of MYRF binding sites in promoter regions of myelination genes [19].
Structurally, the MYRF protein has two functionally isoform, both containing a DNA binding
domain (DBD) with homology to the yeast transcription factor Ndt80 and an intramolecular
chaperone domain (ICD) similar to that in bacteriophage tail spike proteins (Figure 2). In order
to function as a transcription factor, the ICD autoproteolytically cleaves the protein, releasing a
functional trimeric N-terminal fragment that enters the nucleus and directly activates myelin
genes [19] [20].
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While MYRF clearly plays a role in myelination, MYRF has no known role in cardiac
development or LR patterning. Therefore, it is surprising that exome sequencing studies of
patients with congenital birth defects have identified myrf as a candidate CHD/Htx gene (Figure
2, Table A) [17] [21] [22] [23] [24] [25]. Altogether, 14 CHD patents with 13 unique mutations in
MYRF have been identified. Previous analysis of these variants suggest that the frameshift and
stop gained variants result in truncated protein products and decay, whereas the missense
variants in the DBD and ICA are all predicted to be deleterious by a majority of bioinformatic
tools [22]. Furthermore, within the DBD, F378S was thought to affect DNA binding affinity,
Q394H changed surface charge distribution and G426R and L470V destabilized the protein
structure [22].

Figure 2: MYRF schematic with patient variants labeled. Isoform 1 of MYRF is shown in this diagram, with
the DNA binding domain (DBD), intramolecular chaperone domain (ICD), and the transmembrane domain
(TM) labeled. CHD patients identified to have a myrf variant are labeled, and those in red font represent
patients who also had signs of htx. The majority of mutations are point mutations within the DBD or ICD,
but there are also frameshift mutations or splice mutations present. Mutations F378S, Q394H, and L470V
are bolded, as these three mutations were used to create patient mutation mRNA constructs in future
experiments.

In addition to complex CHD, MYRF variants have been identified in other developmental
disorders including congenital diaphragmatic hernia, pulmonary hypoplasia, genitourinary
anomalies (ambiguous genitalia, hypospadias, cryptorchidism) and nanophthalmos [26].
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Table A: MYRF Variant Phenotypes
Variants in red are patients with clinical htx.
Identifier

PCGC-1

PCGC-2

PCGC-3

Pinz-1

De novo
Cardiac Phenotype
Variant
(NM_013279.3)
F378S
aortic arch hypoplasia,
hypoplastic left
ventricle, coarctation
Q394H
aortic arch hypoplasia,
atrial septal defect,
aortopulmonary
collateral artery,
bicommissural aortic
valve, hypoplastic left
heart, hypoplastic mitral
valve
L470V
coarctation,
bicommissural aortic
valve
c.2309+1G>A
Scimitar syndrome,
cortriatriatum

Pinz-2

R805X

Scimitar Syndrome

Chitayat -1

T410RfsX14

Qi-1

G72Wfs*45

Qi-2

G426R

hypoplastic left heart
with rudimentary left
ventricle, aortic valve
atresia, mitral valve
atresia, hypoplasia of
left atrium, tubular
hypoplasia of
ascending aorta, total
anomalous pulmonary
venous connection to
right atrium, dysplasia
of tricuspid valve
Atrial septal defect,
ventricular septal
defect, tetralogy of falot
Ventricular septal
defect

Other Phenotypes

ambiguous genitalia, hypospadias,
undescended testis
Lung hypoplasia, right hemidiaphragm eventration,
undescended testis

Skeletal abnormalities, short
stature
Mild speech delay, pulmonary
hypoplasia, tracheal anomalies
Penoscrotal hypospadias,
micropenis, unilateral
cryptorchidism
Wide nasal bridge, gut malrotation,
persistent urachus, bilateral
descending testes, congenital
diaphragmatic hernia, cleft spleen,
thymic involution, thyroid fibrosis
mild pulmonary hypoplasia,
Ambiguous external genitalia,
poorly defined urethral meatus,
bifid scrotum, no vaginal opening,
right hepatotesticular fusion, left
splenotesticular fusion,
malrotation of small intestine and
meckel band

bilateral undescended testes,
congenital diaphragmatic hernia
accessory spleen, congenital
diaphragmatic hernia,
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Qi-3

V670A

Atrial septal defect,
ventral septal defect
hypoplastic left heart
syndrome

Qi-4

R686H

Qi-5
Qi-6

1877-1G>A
1877-1G>A

Qi-7

Q587*

Scimitar Syndrome
Hypoplastic left heart
syndrome
Dextrocardia

Siggs-1

R1081Wfs*36

Dextrocardia

no internal genital organs, external
blind-ending vagina
congenital diaphragmatic hernia
ambiguous genitalia,
intellectual disability,
congenital diaphragmatic hernia
Unknown
Unknown
Right pulmonary hypoplasia, Swyer
syndrome with female genitalia
High hyperopia

1.5 Xenopus: A Model Organism for Embryonic Development and Genetic Manipulation
The frog model Xenopus has historically been used as a model organism to understand
developmental biology. From its early use as a pregnancy test in the early 1940s-1950s,
Xenopus has played a prominent role in the history of developmental biology, including the
discovery of mitochondrial DNA and its maternal inheritance [27] [28]. Today, two species of
Xenopus, laevis and tropicalis, are most frequently used in research. X. laevis is allotetraploid,
while X. tropicalis is diploid, making it a more convenient model for genetic manipulation [8].
Xenopus is an ideal model organism for studying embryonic development, as it is easily
manipulated and the large clutch sizes allow for systematic and statistical approaches [29].
Development of embryos occurs much more rapidly in Xenopus as opposed to mice, such that
cardiac looping can be easily visualized under light microscopy only three days post fertilization.
Furthermore, evolutional conservation between Xenopus and humans allows for modeling of
human phenotypes in Xenopus. For example, compared to the zebrafish heart, which is two
chambered, the Xenopus heart has three chambers, with two atria and a ventricle [8] [30].
Genetic manipulation can easily be accomplished in Xenopus. Microinjections of mRNA
can be used for gain of function studies. In order to induce loss of function of a gene,
morpholino oligonucleotides (MO) can be used. MOs can be designed to block the translational
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start site on the 3’UTR or against splice site, thereby blocking translation of the mRNA to
protein. More recently, CRISPR based gene modification has been shown to effectively deplete
genes at the DNA level in F0 embryos, revealing early zygotic phenotypes [29]. However, a
weakness to CRISPR based gene modification is the inability to block maternal mRNA from
becoming translated into protein. Uniquely, a one-of-two cell injection technique, where either
the left or ride side of the embryo is manipulated and the other side acts as an internal control,
can be used in Xenopus. This can allow for more nuanced understanding when studying htx,
which is not possible in other disease models. Lastly, efforts by the Xenopus community to
organize full length cDNA and EST libraries as well as create several transgenic lines
engineered with fluorescent proteins fused to promoter regions of relevant markers has allowed
the flexibility to perform a variety of applications
easily [28] [31]. Because of these advantages,
Xenopus has become a common model used to
study CHD/Htx. The Khokha lab has effectively
used this model study a variety of genes that
have been identified through sequencing
studies [16] [15].
1.6 Left-Right Patterning in Xenopus
LR patterning is essential for proper
internal organ situs and morphogenesis. Studies
show that LR asymmetry occurs during late
gastrulation in the left-right organizer (LRO;
mouse node, zebrafish Kuppfer’s vesicle, and
gastrocoel roof plate [GRP] in Xenopus), which
forms in the posterior mesoderm during late

Figure 3: Schematic of the LR Signaling
Cascade. The left-right organizer (LRO) is
formed during late gastrulation with motile
cilia in the middle that drives fluid leftward.
This fluid flow is sensed by the immotile cilia
present on the periphery of the LRO, leading
to a break in bilateral symmetry. The leftward
flow inhibits coco (dand5) on the left side of
the embryo, allowing nodal and pitx2 to be
expressed on the left side of the embryo,
leading to normal LR patterning. Image from
Duncan et al, 2016.
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gastrulation (Figure 3) [32] [33]. In the two-cilia model, motile cilia drive extracellular fluid
leftward in order to break bilateral symmetry. The immotile cilia, located on the periphery of the
LRO, detects this extracellular fluid flow, translating it into asymmetric gene expression [34] [35]
[15]. Importantly, cilia signals repress dand5 (CERL2 in mouse and previously coco in frog), a
nodal antagonist, leading to left-sided nodal signaling. Nodal signals are then relayed to the left
lateral plate mesoderm (LPM), activating left-sided pitx2 expression to properly define the left
and right sides of the embryo [36] [37] [38] [39] [40] [41]. Following activation of this signaling
cascade, cardiac precursors cells that initially form a midline straight heart tube are then able to
loop to the right, establishing cardiac asymmetry [2]. Interestingly, nodal can both positively and
negatively regulate its expression in the LPM. Nodal can induce auto-transcription of itself via
two nodal responsive enhancers [35]. Conversely, nodal induces expression of lefty, a known
nodal antagonist that acts as part of the midline barrier to inhibit nodal expression to only the left
side of the embryo [42].
In addition to the left specific Dand5-Nodal-Pitx2 axis described above, other signaling
pathways have also been implicated in LR patterning [43]. For example, a BMP-mediated right
sided pathway results in activation of the gene prrx1a in the lateral plate mesoderm [44]. Prrx1a
is an epithelial-mechanical transition (EMT) inducer, and it drives LR differential cell movements
towards the midline. Downregulation of this gene prevents proper heart looping, leading to
mesocardia.
1.7 Gastrulation and Cell Specification
Gastrulation refers to the process in which the embryo undergoes cell specification and
cell migration in order to form the three distinct germ cell layers: endoderm, mesoderm and
ectoderm. If this process is perturbed, then the embryo may have defects in tissues derived
from the layer(s) affected. In Xenopus, cell-specification occurs after the midblastula transition,
when the embryonic genome is activated. Gastrulation begins at stage 10, where cells on the
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future dorsal side of the embryo invaginate to form the blastopore. In order to accomplish this
movement, the cells that invaginate to form the blastopore, termed bottle cells, drastically
change their shape such that the main body of the cell is displaced inside the embryo while the
cell also continues to maintain contact with the outside surface. Next, cells within the marginal
zone, where the animal and vegetal poles meet, involute into the blastopore. As gastrulation
proceeds, the blastopore lip widens laterally, and as more cells continue to migrate, a ventral lip
eventually forms. The population of cells that form the blastopore lip also continually changes in
an orderly fashion throughout gastrulation, until all cells specified to become mesoderm or
endoderm migrate to their appropriate positions. Furthermore, while involution is occurring at
the blastopore lip, the ectodermal layers undergo epiboly, such that the ectodermal cell layer
expands over the entire embryo [45].
Spemann and Mangold were the first to show the molecular importance of the
blastopore lip. In fact, the dorsal lip is also termed the Spemann organizer. In a transplant
experiment, they showed that when the dorsal lip was removed from one newt species and
implanted in another, the dorsal lip tissue in the host newt continue to invaginate, and that it
induced the tissue around it to form into the neural tube and dorsal mesoderm tissue [45]. From
this experiment, we now know that the Spemann organizer induces the neighboring tissues to
change their fates and undergo gastrulation in a host embryo even when there is an already
established anterior-posterior and dorsal-ventral axis. Nieuwkoop later showed that the dorsal
most vegetal cells of the blastula are the cells capable of inducing the organizer [45].
Molecularly, there are many pathways that are necessary for gastrulation to occur
successfully. Of note, nodal signaling is essential during this process. In Xenopus, the nodal-like
genes, including nodal1 is expressed in the Spemann organizer, and it is necessary for
mesoderm induction [46]. Abnormal expression of nodal during gastrulation can therefore lead
to defects in mesodermal tissue.
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1.8 The Nodal signaling pathway
The nodal signaling pathway is essential for multiple processes during early
development. Nodal is a secretory protein belonging to the TGF-beta superfamily, which
includes members such as activin and BMP. Similar to other TGF-beta members, nodal is first
secreted as a pro-protein that must be cleaved in order to be fully activated [47]. Furin is a
subtilisin-like protein convertase (SPC) known to convert pro-nodal into its mature form, which
allows nodal to function through its canonical signaling pathway [48]. After cleavage, Nodal
binds to both its co-receptor cripto and a heterodimeric receptor, which phosphorylates
smad2/smad3, allowing the complex to bind to smad4, translocate to the nucleus, and activate
foxH1 and mixer to define cell fate (Figure 4) [49] [50] [51] [52]. Extracellularly, nodal is inhibited
by lefty and cerberus [42] [53].
Furin
Nodal

Nodal

Proprotein
Nodal
Cripto

Smad
2/3

P

Smad
2/3

Smad
4

Nodal Target Genes
Figure 4: The Nodal signaling cascade. Nodal is first secreted as a proprotein, that is then cleaved to its mature
form through furin. Nodal then binds both a receptor and co-receptor (Cripto), which phosphorylates smad2/3. In
doing so, smad2/3 binds to smad4 and translocates to the nucleus where it can activate transcription of nodal
target genes.

12
While chickens, mice, and humans have only one nodal ligand, there are three nodal
ligands in zebrafish (squint, cyclops, and southpaw), and six in Xenopus (nodal1-nodal6). In
Xenopus, dose-dependent nodal expression is important during gastrulation for mesendoderm
formation [54]. In contrast, nodal antagonism via Cerberus is essential for head formation
indicating that precise titration of nodal signaling is essential for proper embryonic patterning
[53] [55]. Nodal signaling also plays a crucial role in LR axis specification, as mentioned above
[56].
1.9 Furin
Nodal protein is first secreted a pro-protein. Therefore, the protein must undergo
cleavage in order to achieve its mature form. Recently, several SPC proteins have been
identified that can cleave TGF-beta protein. Furin (also named SPC1) can specifically cleave
pro-nodal into mature nodal. Interestingly, a study found that Furin-deficient mice embryos
develop severe ventral closure and heart morphogenesis defects [57]. Furthermore, a more
recent study shows that depletion of Furin in cardiac progenitor cells is embryonically lethal with
cardiac outflow defects [58] Other SPCs have also been implicated in LR patterning and early
developmental defects [59]. Therefore, perturbations of SPCs may have a large developmental
impact based on the proprotein molecules they modulate.
Of note, FURIN is encoded by three distinct FUR mRNA isoforms, with differences only
in the 5’untranslated region. The gene has three distinct promoters, P1, P1A and P1B, but the
same start codon located in exon II [60] [61].
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Statement of Purpose
The goal of this proposal is to elucidate the mechanism of myrf’s novel role in LR
patterning and early development. This will provide functional evidence that variants of myrf
result in LR patterning abnormalities in children diagnosed with CHD. Additionally, it will better
elucidate the pathogenesis of CHD and heterotaxy. The overarching goal of this project and the
lab is therefore to gain insight on how genetic variants can lead to disease in order to enable
genetic counseling, prognosis, and therapeutics for a large spectrum of rare diseases.
Xenopus is used as the model organism for this study, as it is ideal for studying
embryonic development. Xenopus has been used for more than a decade to perform gene
modifying research, it is easily manipulated, and it provides large clutch sizes for systematic and
statistical approaches. Additionally, due to the evolutionary conservation between Xenopus and
humans, I can model the human phenotype that occurs with myrf depletion in Xenopus.
2.1 Specific Aims:
1.Determine how myrf depletion perturbs LR patterning
In a series of patients with CHD, exome sequencing studies identified 14 patients with
13 unique mutations in the membrane-bound transcription factor myrf as a candidate CHD
gene. Many of these patients had phenotypes consistent with htx. However, there is no known
role of myrf in cardiac development or LR patterning. Therefore, this study analyzes the
functional role of myrf in early development using the vertebrate model Xenopus.
1A: Evaluate if myrf alters cardiac looping.
1B: Evaluate global markers of LR patterning to determine the functional role of
myrf.
1C: Determine the mechanism of how myrf perturbs the LR signaling cascade
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Successful completion of this aim will determine where in the LR signaling cascade myrf
plays a role and how it functions.
2. Determine the localization and function of myrf in LR patterning.
Previous studies have shown that MYRF autoproteolytically cleaves itself to allow its N
terminus to enter the nucleus and act as a transcription factor to directly activate myelination
genes. However, it is unknown how MYRF affects LR patterning. Therefore, this aim helps
elucidate the structure-function of myrf in LR patterning in Xenopus.
2A: Analyze the function of patient mutations found in the DNA binding domain.
Successful completion of this aim will help determine whether myrf acts as a
transcription factor in the context of LR patterning.
3. Determine how myrf depletion perturbs gastrulation
Preliminary studies suggest that myrf depletion results in delayed gastrulation in
Xenopus. Therefore, I aim to analyze if cell specification is affected during gastrulation through
analysis of gastrulation markers.
3A: Analyze gastrulation markers in myrf depleted embryos.
3B: Determine the mechanism of how myrf affects gastrulation.
Successful completion of this aim will determine if myrf is necessary for proper
gastrulation through affecting cell specification, and if so, how myrf functions in gastrulation.
2.2 Hypotheses:
1. Depletion of myrf results in abnormal organ situs and gastrulation due to excessive
nodal expression.
2. myrf normally acts to regulate nodal expression by inhibiting furin transcription.
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3.0 Methods
3.1 Embryo manipulation
3.1.1 Xenopus husbandry
X. tropicalis were maintained and cared for in our aquatics facility according to
established protocols that were approved by the Yale IRB – Institutional Animal Care and Use
Committee (IACUC).
3.1.2 In-vitro fertilization of Xenopus tropicalis and embryo microinjection
To perform in vitro fertilization, female frogs were primed overnight with 10 units of hCG.
On the day of fertilization, female frogs were boosted with 200 units of hCG. When the female
frogs began laying eggs, approximately 3-4 hours after being boosted, the male frog was
euthanized via decapitation using 0.05% (1x) benzocaine solution as a paralytic, and his testes
were dissected and placed in a microcentrifuge tube. Eggs were manually harvested onto petri
dishes coated with 1xMBS solution with 0.1% bovine serum albumin (BSA). Sperm was
released by crushing the testes in the microcentrifuge tube using a pestle until the solution
becomes cloudy, and the sperm solution was then poured over the eggs. The petri dish was
incubated at room temperature for 3 minutes to allow the sperm to attach to the eggs. Then, the
dish was flooded with 0.1x MBS (pH 7.8-7.9) and incubated at room temperature for 10 minutes.
By the end of the 10 minutes, fertilized eggs could be denoted by constriction of the animal pole.
The MBS solution was removed and replaced with 3% cystine solution (pH 7.8-7.9) for 6
minutes to de-jelly the embryos. The cysteine solution was removed, the dish was washed three
times with 0.1xMBS and left in 3% Ficoll in 1/9 MR solution for microinjections.
Embryos were injected at the one-cell or two-cell stage using a fine glass needle
Picospritzer apparatus, as previously described [62]. In each injection, drop size was calibrated
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to 8nl per injection. After microinjections were completed, embryos were allowed to rest until
they began to divide normally. If a CRISPR sgRNA was injected, both control and experimental
embryos were kept at 28 degrees Celsius for 30 minutes in order to increase the efficiency of
the cas-9 protein. Embryos that divided normally were then sorted and raised to appropriate
stages in 1/9 MR +gentamycin at 25 degrees Celsius [62]. Staging of Xenopus tadpoles were
according to Nieuwkoop and Faber [63].
3.1.3 CRISPR Design and Validation
Small guide RNAs (sgRNAs) containing the following myrf target sites were designed
from the v7.1 model of the X. tropicalis genome: CRISPR-1 (exon 2) 5’CGGGGCCAGGGACAACATGTGGG-3’, CRISPR-2 (exon 11) 5’GTGAGGTGCTGTGGCAACGTGGG-3’, CRISPR-3 (exon 2) 5’GGGCCAGGGACAACATGTGGGGG-3’ . Embryos were injected with 400pg of targeting
sgRNAs and 1.5 ng cas9 protein (CP03, PNA-Bio) to genetically knockdown myrf in F0
embryos, as described previously [29].
To verify knockdown of myrf, F0 embryos were raised to stage 45, and DNA was
extracted using the DNeasy Blood and Tissue Kit (Qiagen). Editing by CRISPR-2 and 3 in F0
embryos were assessed by amplifying a 500 bp fragment around the prospective cut site and
performing the T7 endonuclease assay [64]. In this process, PCR products of control and
experimental embryos were denatured and re-annealed, and mismatched products were
detected by T7 Endonuclease I Digest (NEB). Digests were visualized on 2% agarose gels,
where two separate bands were visualized in embryos with DNA level changes due to the
CRISPR. CRISPR-1 was also verified by amplifying a 200 bp upstream and 500 bp downstream
fragment of tadpole genomic DNA around the prospective cut site in myrf, Sanger sequencing
and subsequent ICE (Interference of CRISPR Edits) analysis with Synthego software [65]. The
following primers were used to produce PCR products containing the prospective cut sites:
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sgRNA

Target Site (5’-3’)

Forward Primer

Reverse Primer

1

CGGGGCCAGGGACAACATGTGGG

TTTGATTGAGCCCCTTCGCT

GCAACACTTAAAAGCCCCAGT

2

GTGAGGTGCTGTGGCAACGTGGG

TACTTGGTGGCAGCACAATC

ATCCACCTGAAAATGCAAGG

3

GGGCCAGGGACAACATGTGGGGG

CCTCAGCCTTGTGGATCTTC

AAACACCTGGCATCCAGAAC

3.1.4 Morpholino Oligonucleotides Design
Morpholino oligonucleotides (MO) were designed against the start site of Xenopus
tropicalis nodal1 (start site MO sequence 5’ to 3’: ACAGGACTGCTGTCAGAAATGCCAT) and
obtained from Gene Tools LLC. 2-5 ng of MO was injected at the one cell stage and 1ng at the
two-cell stage to deplete nodal1. Furin ATG blocking MO1(GCAGTAAACTGGGCAACAGATCCAT) and MO-2(GCAGTAAACTGGGCAACAGATCCA)
morpholino oligonucleotide were also obtained from Gene Tools LLC, and 5ng of both MOs
were injected at the one cell stage to deplete furin.
3.1.5 mRNA Microinjections
Full length human MYRF was obtained from the Harvard Plasmid Database
(HsCD00348407) and subcloned into the pCSDest2 vector using Gateway recombination
techniques. Capped mRNAs were generated in vitro by first linearizing using HPA1 and
transcribing with mMessage machine SP6 polymerase kit (Ambion), following the
manufacturer’s instructions. To create patient mutation constructs, site-directed mutagenesis
was conducted on wild-type MYRF according to standard methods using Q5 Site-Directed
Mutagenesis Kit (New England BioLabs) [66]. The following primers were designed for each
patient mutation, and the nucleotide change was confirmed through Sanger sequencing:
F384S

GGGCTTCACtcaTCGGTGGGCG

TTGTCCGCATCCACGCGG

QH

GAACAACTTCcacGTGACAGTGTAC TTCTTCTGGCACACAAAG
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L470V

TGTGGGGCGGgtaCACTTCAGCG

GTCACCTTCGTGACCTGCTC

The mutated DNA was then linearized using HPA1 enzyme and mRNA generated using
mMessage mMachine SP6 polymerase. Microinjections of mRNA was performed by injecting
500pg of all four MYRF mRNA constructs at the one cell stage.
3.1.6 Cardiac Looping Scoring
Stage 45 Xenopus tadpoles were paralyzed with benzocaine and scored ventrally under
a stereomicroscope. Looping was determined by the position of the outflow tract, where D loops
were defined as outflow tracts directed to the right, L loops to the left, and A loops midline.
3.1.7 Gastrocoel Roof Plate Explants.
Gastrocoel roof plates (GRPs) were dissected at stages 14 and 16. The embryo was
dissected transversally perpendicular to the anterior-posterior plane. The GRP can then be
visualized in the posterior dorsal tissue and removed.
3.2 Molecular and Cellular Techniques
3.2.1. Whole Mount In situ Hybridization
Digoxigenin-labeled antisense probes for pitx2 (TNeu083k20), coco (TEgg007d24),
nodal1 (TGas124h10), gdf3, xnr3 (Tgas011k18), foxj1 (Tneu058M03), chordin (Tgas133K5),
xbra (TNeu024F07), gsc (TNeu077f20), vent2 (BG885317), wnt8 (TGas015M15), myoD, and
myf5 (TGas127b01) were in vitro transcribed with T7 High Yield RNA Synthesis Kit (New
England Biolabs E2040S). furin IMAGE clone was obtained from the Harland Lab. To create an
antisense probe for myrf, PCR was performed on Xenopus tropicalis stage 12 cDNA with the
following primers: 5’-CCCCGGATCAAGTCACTAAA-3’ and 5’-TGCACTTCCTGAGCAATCAC3’. The PCR product was cloned into topo vector and plated with x-gal for blue-white screening.
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The DNA was linearized using ECORV, and mRNA was generating using T7 High Yield RNA
Synthesis Kit.
Embryos were raised and collected at desired stages, fixed in MEMFA for 1-2 hours at
room temperature and dehydrated in 100% methanol. GRPs were dissected post fixation prior
to dehydration. Whole mount in situ hybridization (WISH) was performed, where embryos were
incubated in digoxigenin-labeled antisense probes overnight. The labeled embryos were then
washed, incubated with anti-digoxigenin-AP Fab fragments (Roche 11093274910), and signal
was detected using BM-purple (Roche 11442074001), as described in detail [67]. Embryos were
fixed in 0.5% Glutaraldehyde in PFA and bleached. Embryos were photographed in methyl
cellulose.
3.2.2 Protein Extraction
For total embryo western blots, pools of 10 control and treated embryos were collected
at stage 11 or stage 28 in 150 ul of 1x RIPA buffer (EMD Millipore Corp, 20-188) with
phosphatase/protease inhibitor (Thermo Scientific, 1861281). Embryos were lyzed and
centrifuged at 4 degrees for 10 minutes to separate lysate from lipids and debris. The fat and
debris layers were removed, and the sample was centrifuged again for 10 minutes at 4 degrees.
The lysate was separated again and either used immediately for western blot or frozen at -80
degrees.
3.2.3 Western Blotting
Western blotting was carried out following standard protocols and 20 ug of protein was
loaded into each lane in Bolt 4-12% Tris-Bis gels (Invitrogen NW04125BOX or NW04120BOX).
Transfer followed a semi-dry transfer module based on Invitrogen’s established protocol. After
transfer, PVDF membranes were blocked with 5% BSA for 1 hour followed by primary antibody
at 4 degrees overnight. Anti-myrf (Abcam ab213681, 1:500 in 5% BSA), anti-psmad2 (Cell
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signaling technologies #3108, 1:500 in 5% BSA), anti-smad2 (cell signaling technologies #3122,
1:500 in 5% BSA), anti-furin (Santa Cruz sc-133142, 1:500 in 5% BSA), and anti-GAPDH
(Novus 6C5, 1:10,000 in 5% BSA) primary antibodies were used. Membranes were then
washed in 1x TBST and incubated in secondary for 2 hours at room temperature. Anti-mouse or
anti-rabbit HRP conjugated secondary antibodies were used (Jackson Immuno Research
Laboratories, 715–035–150 or 211–032–171 1:10000 dilution). Finally, membranes were
washed in TBST and developed with Amersham ECL Western Blot Detection Reagents (GE
Healthcare). Bands were quantified using ImageJ and relativized to controls. Western Blots
were done in three replicates.
3.3 Statistical Analysis
For Xenopus experiments, we estimated 20-25 samples per experimental condition were
necessary for statistical significance given the magnitude of the changes expected. Typically,
many more samples were obtained for each experiment. Each experiment was performed at
least three times unless otherwise stated. There were no cases where we excluded samples
except in cases of technical failure (embryos were found to be uninjected, in situ hybridization
failed, etc). Statistical significance is reported in the figures and legends, with statistical
significance defined as p<0.05. in-situ results were analyzed by chi-squared test.
3.4 Roles
With the guidance of Khokha lab members, I independently performed the above
protocols, collected data, and analyzed the data presented in this thesis.
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4.0 Results
4.1 Validating Loss of myrf in myrf CRISPR Injected Embryos
Since MYRF was identified in multiple patients with Htx and CHD, we began our studies
by examining the role of MYRF in patterning the LR axis. To investigate whether myrf is
required for LR patterning and cardiac development, we performed F0 CRISPR gene editing in
X. tropicalis. We generated three sgRNAs that target three non-overlapping sites within the myrf
locus (CR1-3) and confirmed genomic editing using either two assays: Sanger sequencing and
ICE (interference of CRISPR edit, Synthego) or T7 Endonuclease (Figure 5). In the first method,
PCR of genomic DNA amplifies DNA around the target cut site in control and experimental
embryo DNA. The Synthego software can then align the control and experimental DNA to look
for frameshift mutations that would result in knockdown of the target gene. CR-1 was analyzed
in pools of 5 embryos using ICE, which showed that CR-1 caused a mutation 90% of the time,

Figure 5: Validation of CRISPR A) ICE was used to validate CR-1. 4 pools of five CR-1
injected embryos were used. Synthego software compared control and experimental DNA
sequences to determine the percentages of mutations that were present in the experimental
pool samples as well as the percentage of mutations that lead to a frameshift or loss of
function. In all four pools, there was a mutation rate of 90% (data not shown), and of those
mutations, the percentage of mutations that caused a frameshift ranged from 31-60%. B-C)
CR-2 and CR-3 were validated using T7 Endonuclease assay. B) Wildtype samples are
shown pre-cut with T7 Endonuclease enzyme (1a) and post-cut (1b). Compared to wildtype
samples, the post-cut CR-2 samples had an additional band, suggesting there was an
additional mismatch in PCR samples due to mutation in the DNA of the experimental samples
caused by the CRISPR. C) Again, the post-cut CR-3 samples (1b, 2b, 3b) had an additional
band compared to the control samples.
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and of these mutations, 30-61% resulted in a frameshift. This demonstrates that CR-1 was
effective in causing a knockdown 31-60% of the time in the F0 embryos (Figure 5A). In the
second method, PCR products around the cut site are denatured and re-annealed, and
mismatched products identified and broken down by T7 Endonuclease. CR-2 and CR-3 were
validated using this second method. Both CRISPRs were digested by T7 Endonuclease, as
seen by the additional band when run on an agarose gel, which suggests that both CRISPRs
effectively edit the DNA (Figure 5B-C).
4.2 Loss of myrf Results in LR Patterning Defects
Initially, the primitive heart tube is midline, but during cardiac morphogenesis, the
cardiac outflow tract loops to the right which is dependent on normal patterning of the LR axis. If
the LR axis is not established properly, the outflow tract can loop to the left (L loop) or remain
midline (A loop) (Figure 6A). To determine if myrf plays a role in LR patterning, we raised F0
edited embryos to tadpole stage (stage 42-45) and examined the outflow tract of the heart in
comparison to uninjected control embryos. Uninjected control embryos (n=816) had 2.57%
looping abnormalities (1.72% L loops and 0.86% A loops) whereas myrf depleted embryos

Figure 6: Depletion of MYRF results in abnormal heart looping. A) Stage 45 Tadpoles
imaged ventrally are shown with the heart outlined in black. Normally, the outflow tract of the
heart loops to the right, as illustrated on the image on the left, whereas if LR patterning is
perturbed, the outflow tract can be midline (A-loop) or loop to the left (L-Loop). B) Compared
to uninjected control embryos, myrf depleted embryos, which was accomplished using three
separate CRISPRs, resulted in abnormal heart looping defects, the majority being A-loops.
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(n=563; 256; 95) had looping defects of 13.5%, 15.23% and 15.79% with CR-1, CR-2 and CR-3
respectively, with the majority of looping defects being A loops, ranging from 11-13.7% (Figure
6B). This indicates that myrf is required during cardiac morphogenesis, and loss of myrf results
in improper LR development.
4.3 myrf is Required for Global LR Patterning
Next, to determine if myrf regulates global LR patterning, we examined gene markers
pitx2 and coco. In wild type embryos, cilia signaling leads to LR asymmetry of coco such that
coco expression is reduced on the left compared to the right, which eventually leads to the
activation of pitx2 on the left lateral plate mesoderm (Figure 7A). Comparing F0 edited embryos
(n=185) to uninjected control embryos (n=187), myrf depleted embryos displayed 21.8%
abnormal pitx2 expression to only 5.3% in uninjected control embryos (Figure 7B), indicating
that myrf acts upstream of pitx2. Interestingly, the majority of the pitx2 defects in the F0 edited
embryos were bilateral expression, with myrf depleted embryos demonstrating 16.2% bilateral
pitx2 expression compared to 4.3% in uninjected control embryos.
To confirm the bilateral pitx2 expression phenotype was specifically due to depletion of
myrf in the CR-1 injected embryos, we conducted an experiment where we co-injected embryos
with both CR-1 and human wildtype MYRF mRNA. By providing exogenous MYRF mRNA to
embryos depleted of myrf we hoped to “rescue” the LR patterning defects, which we measured
by evaluating pitx2 expression. In doing so, we found that co-injected embryos (n=52) had
significantly decreased pitx2 defects, specifically with only 5.8% of bilateral pitx2. We also
showed that overexpression of wildtype MYRF mRNA alone did not result in significant pitx2
defects, with 4.7% overall pitx2 defects and 3.1% bilateral pitx2 expression (Figure 7B).
Together, this suggests that the LR patterning defects seen in the F0 edited embryos is
specifically due to loss of myrf.
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Figure 7: Depletion of MYRF results in bilateral pitx2 expression. A) Stage 28
tadpoles expressing pitx2, demarcated by the red arrowhead. Normal expression of
pitx2 is on the left LPM. However, with abnormal LR pattering, pitx2 can be
expressed on the right, bilaterally or be completely absent. B) Compared to
uninjected control embryos, CR-1 injected embryos had an increase in abnormal
pitx2 expression, the majority showing bilateral expression. However, this
abnormality could be rescued with co-injection of human wildtype MYRF mRNA.

Bilateral pitx2 expression could be the result of bilateral repression of coco at the LRO,
whereas normally post-flow expression of coco should be greater on the right than the left
(Figure 8A). However, expression of coco at stage 19, where cilia based signaling is complete,
was normal in myrf depleted embryos (n=83) with 20.5% coco defects when compared to
uninjected control embryos (n=92) with 18.5% coco defects (Figure 8B). Although the rate of
abnormal coco expression is high in uninjected control embryos, this is most likely due to
difficulty in subjectively evaluating GRP marker expression. Furthermore, the proportion of each
type of abnormality (absent expression, left greater than right expression, and left equal to right
expression of coco) were similar in both control and myrf depleted embryos. This, along with the
large sample size, is reassuring, and we can conclude that the percentage of abnormal coco
expression in myrf depleted embryos is similar to that in uninjected control embryos. This result
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suggests that the LRO is properly specified and is capable of appropriately breaking LR
symmetry. To confirm that the LRO is appropriately specified, we also analyzed pre-flow
expression of coco and found the percentage of abnormal coco expression in myrf depleted
embryos (n=83) to be 38.2%, which was not significant different uninjected control embyros (
n=83) with 31.3% abnormal expression (Figure 8C). We also analyzed both pre and post-flow
expression of LRO markers derriere and nodal1. (Figure 8D-G). At pre-flow stages, 25.4% of
myrf depleted embryos (n=59) showed abnormal nodal1 expression (Figure 8D), and post-flow
stages 22.2% of myrf depleted embryos (n=63) had abnormal nodal1 expression patterns
(Figure 8E). This is not significantly different from uninjected control embryos (n=68 at stage 16
and n=56 at stage 19) that demonstrated 13.2% abnormal nodal1 expression at stage 16 and
33.3% at stage 19. Similarly, pre-flow abnormal expression of derriere was 6.6% in myrf
depleted embryos (n=91) and 11.6% in uninjected control embryos (n=95) (Figure 8F), and
post-flow abnormal expression of derriere was 18.6% in myrf depleted embryos (n=70) and
11.3% in uninjected control embryos (n=71) (Figure 8G). In all cases, there was no statistically
significant difference in abnormal marker expression in myrf depleted embryos. Therefore, we
conclude that the LRO is appropriately specified in myrf depleted embryos, and that myrf
regulates the LR patterning cascade downstream of cilia signaling in the LRO, but upstream of
pitx2.
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Figure 8: Depletion of MYRF does not perturb LRO formation. A) At pre-flow stages (stage 16),
coco is normally expressed equally on the left and right sides of the LRO. However, at post-flow
stages (stage 19), coco is normally expressed more on the right side. B-C) When myrf is
depleted, there is no change in abnormal coco expression at both stage 16 and stage 19. D)
Nodal1 is normally expressed equally bilaterally at both stage 16 and 19. E) There was no
significant difference seen between control and myrf depleted embryos in nodal1 expression at
both stages 16 and 19. F) Derriere is normally expressed equally bilaterally at both stages 16
and 19. F) There was no significant difference seen between control and myrf depleted
embryos in derriere expression at both stages 16 and 19.

4.4 myrf is Required to Regulate Temporal and Spatial Expression of nodal1
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Because myrf depleted embryos resulted in abnormal pitx2 expression, but normal coco
expression, we hypothesized that myrf acts downstream of LRO signaling. In LR patterning, cilia
signaling in the LRO establishes asymmetric activation of the nodal pathway eventually in the
lateral plate mesoderm, which leads to pitx2 expression on the left side [33] [68] [69]. Therefore,
we hypothesized that nodal signaling in the lateral plate mesoderm may be abnormal with myrf
depletion. First, we used WISH to visualize nodal1 expression. At stage 24, nodal1 is normally
expressed in the left LPM. In control embryos (n=31) and myrf depleted embryos (n=42), nodal1
was indeed predominantly expressed only on the left side. However, despite being expressed in
the correct location, we observed an increase in intensity of nodal1 expression and area of
expression in myrf depleted embryos (Figure 9A). When we quantified the number of embryos
that showed this increase intensity and area in control and myrf depleted embryos (32.3% and
64.3% respectively), we found that this difference was statistically significant.
Examining earlier stages (stage 22), we visualized marked bilateral nodal1 expression in
42.1% of myrf-depleted embryos (n=19) compared to only 8.3% in uninjected control embryos
(n=13) (Figure 9B). At later tailbud stages (stage 28), when nodal1 expression normally ceases
within the left LPM, we noticed persistent left-sided nodal1 expression in myrf depleted
embryos, as denoted with the arrowhead in Figure 9C. When quantified, 48.6% of myrf depleted
embryos (n=35) showed sustained expression of nodal1 whereas only 17.2% of uninjected
control embryos (n=29) visualized persistent nodal1 expression, which was a statistically
significant difference. This suggests that myrf functions to repress temporal and spatial
expression of nodal1, and the early bilateral nodal1 expression could lead to bilateral pitx2
expression in myrf depleted embryos.
To test if myrf phenotypes are due to excessive nodal signaling, we co-injected CR-1
with a sub-optimal dose of nodal1 MO (nMO) and found that the co-injected embryos (n=83)
had significant rescue of the bilateral pitx2 expression, with only 1.2% of embryos
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Figure 9: Depletion of myrf results in abnormal nodal signaling. A) Visualization of nodal1
expression at stage 24. Normally, nodal1 is expressed in the left LPM, as seen in the control
embryo. This was also true in the myrf depleted embryo. However, there was an increased
intensity and area of expression in myrf depleted embryos, and this difference was significant
when quantified. B) At earlier stages, myrf depleted embryos had bilateral expression of nodal1,
which was statistically significant when quantified. C) At later stages, when nodal1 expression at
the LPM normally ceases, myrf depleted embryos had persistent expression of nodal1. D) Coinjection of nodal1 morpholino was able to rescue the bilateral pitx2 phenotype. E) Depletion of
myrf leads to increased P-smad2 concentration, which is rescued with co-injection of nodal1
morpholino. Injection of nodal1 morpholino alone results in decreased P-smad2 levels.
demonstrating bilateral pitx2 expression (Figure 9D). Of note, the co-injected embryos had a
high percentage of absent nodal1 expression (14.5%); however, when nMO was injected alone
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(n=65), there was a similar high percentage of absent nodal1 expression (10.8%), which
suggests that this absent phenotype is background from the nMO injection.
Lastly, to confirm that the LR patterning abnormalities are due to excessive nodal
signaling, we performed a Western Blot to analyze the relative amount of phosphorylated smad2 (P-smad2) levels that were present in the various experimental conditions of the above rescue
experiment. The amount of P-smad2 was compared to both total smad-2 and GAPDH protein
levels in the cell lysates of the four different experimental conditions. Compared to uninjected
control embryos, there was a 124% increase in P-smad2 protein levels in CR-1 injected
embryos, and P-smad2 protein returned to normal levels when embryos were co-injected with
nMO (Figure 9E). To confirm that nMO functioned as expected, we noted an appropriate loss in
P-smad2 levels in embryos injected with nMO alone. This indicates that myrf depletion leads to
excess nodal1 signaling, which can then be rescued with nodal1 depletion.
4.5 myrf Is Necessary to Restrict Left-sided nodal1 Expression
In our results above, depletion of myrf leads to inappropriate nodal1 expression and
activation of pitx2 expression on the right and expansion/persistence of nodal1 expression on
the left LPM. There are three mechanisms that normally limit nodal1 to the left side: first, nodal1
is repressed on the right LPM of the embryo [70] [71] [72], second, a midline barrier limits
nodal1 secreted protein to the left side of the embryo [73] [74] [75], and third, nodal1
experiences negative feedback on the left side to contain its expression [42] [76]. In order to
better distinguish whether myrf played a role in one of these three functions, we first performed
one of two-cell injections in order to deplete myrf on only one side of the embryo. In Xenopus,
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by injecting into one cell of the two-cell embryo, one
can select embryos in which the injection is targeted
to either the right or left side of the embryo. If myrf is
necessary on the right side, then it may repress
right sided nodal1 expression. If myrf is necessary
on the left side, then it may prevent excessive left
sided nodal1 signaling to “leak” over to the right
side. In completing this experiment, we found that
left-sided myrf depleted embryos (n=206) displayed
16.5% abnormal heart looping compared to only
3.1% in uninjected control embryos (n=289), which
was statistically significant (Figure 10A). However,
right-sided myrf depleted embryos (n=188) resulted
in normal organ laterality (4.9% abnormal heart
looping). Furthermore, when looking at pitx2
expression, compared to uninjected control
embryos (n=61), which had 3.3% total pitx2 defects
and 0% bilateral pitx2 defects, left-sided myrf
depleted embryos (n=67) resulted in a significant
increase of abnormal pitx2 expression (20.9%) and
bilateral pitx2 expression (14.9%), whereas right-

Figure 10: Depletion of MYRF on the left
side of the embryo results in abnormal LR
patterning. A) Compared to uninjected
controls, depletion of myrf on the left, but
not the right, results in abnormal heart
looping. B) Compared to uninjected
controls, depletion of myrf on the left, and
not the right, results in abnormal pitx2
expression.

sided myrf depleted embryos (n=64) did not have a significant increase of abnormal pitx2
expression (6.3%) or bilateral pitx2 expression (1.6%) (Figure 10B). These results suggest that
myrf is not necessary to repress nodal1 on the right side of the embryo, and instead, either
maintains a functional midline barrier or limits nodal1 expression to the left side of the embryo.

31
Based on this result, we next
sought to examine the midline barrier. We
performed WISH to examine expression of
the midline barrier gene, lefty, at stage 24,
where it functions to limit nodal1 to the lefthand side of the embryo. We found
expression of lefty to be normal in myrf
depleted embryos (n=51), with no gaps in
expression throughout the dorsal midline
(Figure 11A). We also evaluated the
expression of midline genes shh, foxa2,
and xnot at stage 19 and found these
markers to be normal in myrf depleted
embryos (Figure 11B). Together, this
indicates that the midline is appropriately
maintained in myrf depleted embryos.
However, we cannot rule out the possibility
that myrf is required for barrier function.
Indeed, WISH for myrf shows that in early
stages of development, myrf is expressed
in the midline (Figure 11C).
Since myrf is not required on the
right side of the embryo or in the midline,
we hypothesized that myrf functions on
the left side of the embryo to restrict left

Figure 11: Depletion of MYRF does not affect
the midline barrier. A) Lefty expression
remained normal in myrf depleted embryos,
shown by the red arrowheads. B) Expression
of midline markers shh, foxa2, and xnot were
all normal in myrf depleted embryos. C) myrf
mRNA expression was visualized via WISH
and indicated by the red arrowheads.
Throughout various stages of development,
myrf expression can be seen clearly in the
midline of the embryo.
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sided nodal1 signaling. There are two ways in which bilateral nodal expression can occur.
Firstly, there could be a loss of nodal1 inhibition on the left side of the embryo such that there is
a surplus of nodal1 ligand that can then diffuse across the saturated midline barrier.
Alternatively, nodal1 is known to activate transcription of itself through a positive feedback loop
as first described in mice [77]. Therefore, excessive left-sided nodal1 expression could lead to
an amplification of nodal1 expression and induction of nodal1 mRNA in the right LPM.
Therefore, this model predicts that inappropriate right-sided nodal1 mRNA expression and
subsequent ligand secretion is critical for right-sided pitx2 expression as opposed to just
diffusion of nodal1 ligand from the left to the right side. If our model is correct, then depletion of
nodal1 via MO on the right should rescue bilateral pitx2c expression, whereas nMO would be
ineffective if nodal1 ligand was simply diffusing over from the left. Using pitx2 expression as our
marker for LR patterning, we round that
co-injection of nMO on either the right
(n=70) or left side (n=66) was able to
rescue the bilateral pitx2 phenotype
(Figure 12). In fact, co-injection on the left
side resulted in 0% bilateral pitx2
expression and co-injection on the right
resulted in 2.9% bilateral pitx2
expression. This is in comparison to 1.2%
of bilateral pitx2 expression in uninjected
control embryos (n=86) and 18.5% of
bilateral expression in CR-1 injected
embryos.

Figure 12: Loss of myrf results in induction of nodal
mRNA on the right side of the embryo. CoDepletion of nodal1 on either side of a myrf
depleted embryo rescues the bilateral pitx2
phenotype.
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Figure 13: Four hypothesis for right sided nodal expression. A) myrf acts on the right side of the
embryo to inhibit nodal1. However, this is unlikely, as loss of myrf on the right side did not
result in LR patterning abnormalities. B) myrf is necessary to maintain the midline barrier.
However, depletion of myrf did not affect midline barrier genes. C) myrf inhibits nodal1 on the
left side. Loss of myrf leads to excessive nodal1 ligand, which can then diffuse across a
saturated midline barrier. This was found to be unlikely as depletion of nodal1 on the right side
of the embryo rescued the LR defect. D) myrf inhibits nodal1 on the right side, leading to
increased nodal transcription and induction of nodal mRNA on the right side. Our data is in
support of this model.
Taken together, we found that loss of myrf on the right side of the embryo does not
result in LR patterning abnormalities, suggesting that myrf does not directly modulate nodal1
expression on the right side (Figure 13A). We next found that the midline marker is maintained
in myrf depleted embryos. Therefore, it is unlikely that the barrier is weakened such that nodal1
ligand can diffuse across. Finally, our data suggests that loss of myrf leads to excessive nodal1
expression on the left side of the embryo, and through positive feedback, the left-sided nodal1
signal induces nodal1 mRNA on the right side leading to bilateral pitx2 expression and abnormal
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LR patterning (Figure 13D). This is as opposed to excessive nodal1 ligand saturating the
midline barrier and diffusing across (Figure 13C).
4.6 myrf acts as a Transcription Factor to Affect LR Patterning
In the context of myelination, myrf acts as a transcription factor; however, we can only
presume that myrf also acts as a transcription factor in the context of LR patterning. We noted
that five CHD patients have point mutations in the MYRF DNA binding domain [21], which would
suggest that myrf could transcriptionally regulate LR patterning. To determine if this is true, we
generated human MYRF constructs with patient missense variants (F378S, Q394H, and L470V)
which lie in the DNA binding domain. Overexpression of wildtype human MYRF mRNA (n= 157)
resulted in a gain of function phenotype, with 13.4% of abnormal heart looping (11.5% L-loops
and 1.9% A-loops) at stages 42-45, whereas overexpression of the patient variants F387
(n=152), Q394H (n=106) and L470V (n=185) did not result in significantly increased abnormal
heart looping at 3.9%, 4.7%, and 5.9% respectively (Figure 14A). This is in comparison to
uninjected control embryos (n=159), which had 1.9% abnormal heart looping. This result
suggests that overexpression of myrf also has a devastating effect on the LR patterning axis
during development, and the DNA binding domain of MYRF must be functional for proper LR
patterning.
To confirm that MYRF acts as a transcription factor in LR patterning, we performed a
rescue experiment where embryos were co-injected with both CR-1 to deplete myrf and a
patient variant MYRF mRNA. Again, when embryos were co-injected with wildtype MYRF
mRNA with a functional DNA binding domain, we showed that we were able to rescue the
abnormal pitx2 phenotype. However, when we co-injected the patient variant constructs, we
were unable to rescue the LR phenotype (Figure 14B). Co-injection of the F387S myrf mRNA
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Figure 14: MYRF acts as a transcription factor in LR patterning. A) Overexpression of wildtype
MYRF mRNA results in heart looping defects. However, the patient mutation constructs do not
cause LR patterning defects, suggesting that the DNA binding domain is necessary for MYRF to
function in LR patterning. B) While co-injecting wildtype MYRF mRNA rescues the bilateral pitx2
phenotype, co-injection with the patient mutation constructs does not rescue the pitx2 defect,
suggesting that the DNA binding domain is necessary for LR patterning. C) Western blot shows
that there was an equal amount of MYRF protein present in all four experimental conditions.
construct (n=87) resulted in 38.3% pitx2 defects (26.7% bilateral pitx2), co-injection of the
Q394H myrf mRNA (n=98) resulted in 26.5% overall pitx2 defects (17.3% bilateral pitx2), and
co-injection of the L470V myrf mRNA construct (n=60) resulted in 26.5% overall pitx2 defects
(15% bilateral pitx2). It is possible that the difference in pitx2 rescue in co-injecting wildtype
mRNA as opposed to a patient variant mRNA may be due to differences in protein levels of
myrf. For example, it is possible that the protein variant mRNAs produce a MYRF protein that is
unstable and degrade in the cell. To test this, we examined protein levels by Western Blot. As
shown in Figure 134, there was an equal amount of MYRF protein in all four experimental
conditions when relativized to expression of GAPDH protein. This indicates that the loss of
function in MYRF patient variants is not due to instability of the protein, but likely a defect in
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DNA binding ability. Together, these results validate that the patient variants are indeed a loss
of function and that an intact DNA binding domain is necessary for LR patterning.
4.7 myrf is also Necessary to Restrict nodal1 during Gastrulation

Figure 15: Depletion of MYRF results in delayed gastrulation due to abnormal nodal
signaling. A) Compared to uninjected control embryos, which do not have an open
blastopore at stage 19 and no posterior defects at stage 35, myrf depleted embryos showed
signs of gastrulation defects at both stages. B) Compared to control embryos, myrf depleted
embryos had transient loss of myf5 and myod markers. C) Depletion of myrf results in
increased nodal1 expression at gastrulation stages, whereas overexpression of wildtype
myrf mRNA leads to loss of nodal1 expression. D) Co-injection with nodal1 morpholino
rescues the gastrulation defect seen in myrf depleted embryos
In addition to LR patterning abnormalities, myrf depleted embryos resulted in
gastrulation delay (Figure 15A). We observed at neurulation stages that myrf depleted embryos
had an open blastopore while control embryos had successfully undergone gastrulation and did
not have an open blastopore. This resulted in significant posterior defects that persisted at later
stages, such as the split tail phenotype. During gastrulation, cells are specified and then migrate
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to specific location based on their future function. Therefore, if gastrulation does not occur
correctly, this could be due to a cell specification problem or an issue with cell migration. To
determine if cell specification was affected, we analyzed known gastrulation markers and noted
that when compared to control embryos, myrf depleted embryos had defects in paraxial
mesoderm markers myoD and myf5, which are normally present bilaterally dorsal-laterally
(Figure 145). Both myoD and myf5 mark future somatic tissue, and at early stages of
gastrulation myrf depleted embryos showed an asymmetric loss of myf5 and complete loss of
myoD. This loss of paraxial marker expression was transient, as myf5 expression returns at
stage 12, and myoD expression returns at stage 13-14 before neurulation begins (data not
shown).
Surprisingly, myrf depleted embryos also had increased expression of nodal1 during
gastrulation. Conversely, embryos injected with wild type MYRF mRNA resulted in loss of
nodal1 expression during gastrulation (Figure 15C). To determine if we could also rescue the
gastrulation defect in myrf depleted embryos with nodal1 depletion, we co-injected myrf
depleted embryos with nMO (Figure 14D). While 19.9 % of CR-1 only injected embryos (n=201)
had gastrulation defects, determined as an open blastopore at stage 18 or later, embryos coinjected with CR-1 and nMO (n=171) had a significantly lower rate of gastrulation defects at
7.6%. This is in comparison to uninjected control embryos (n=167), which had a gastrulation
defect rate of 1.2%, and nMO only injected embryos (n=159), which had a gastrulation defect
rate of 3.8%. This confirmed that myrf acts to restrict nodal1 for both proper LR patterning and
gastrulation. Interestingly, co-injection of nMO was unable to rescue myoD expression (data not
shown), suggesting that delayed paraxial mesoderm marker expression in myrf depleted
embryos is not downstream of excess nodal signaling. Lastly, all other gastrulation markers
were noted to be normal in myrf depleted embryos (Figure 16).
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Figure 16: Gastrulation markers in myrf depleted embryos. All other gastrulation markers tested
were found to be normal.

4.8 myrf Represses furin
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Although our data suggested that myrf regulates nodal1, it was unclear if this was done
directly or indirectly. In other words, because our data suggests myrf acts as a transcription
factor in the context of LR patterning, the next question we wanted to answer was if myrf directly
alters nodal1 transcription as a transcription inhibitor, or if myrf alters the transcription of another
gene that then affects nodal1. Previous ChIP-Seq analysis completed on mice oligodendrocytes
had identified targets, including smad7 [19]. This was promising, as smad-7 is an inhibitor smad
protein that works to block smad2 from complexing with smad4 and translocating into the
nucleus [78]. Our initial hypothesis was that loss of myrf results in decreased smad-7
transcription, which in turn would cause
decrease regulation of nodal1. However,
we found no difference in smad-7
expression in control and CRISPR-injected
embryos using WISH (Figure 17).
A different study performed RNA
seq in HeLa cells transfected with wild type
MYRF and a catalytic residue mutant and

Figure 17: Smad7 Expression in control and myrf
depleted embryos. Smad7 Expression is indicated by
the red arrowheads. There were no defects in smad7
expression in myrf depleted embryos.

found the gene furin to be among the top
ten most differentially expressed [20]. Furin is a proprotein convertase important in the
maturation process of nodal1 protein [48]. It is possible that if myrf transcriptionally inhibits furin,
depletion of myrf results in increased furin protein, which leads to increased mature nodal1. To
first see if loss of furin results in a phenotype, we performed F0 CRISPR gene editing of furin in
Xenopus tropicalis. We found that compared to control embryos (n=172), which had 1.7% heart
looping defects (1.7% L-loops, 0% A-loops), furin depleted embryos (n=209) had 6.2% heart
looping defects (5.3% L-loops, 0.9% A-loops), which was a statistically significant increase
(Figure 18A). Furthermore, furin depleted embryos (n=57) had an increased percentage of
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abnormal pitx2 defects, with a total rate of 22.8%. This is in comparison to control embryos
(n=51), which only had 2.0% abnormal pitx2 expression (Figure 18B). Interestingly, the majority
of pitx2 defects present in furin depleted embryos were absent expression, which could be
considered the “opposite” phenotype from the bilateral pitx2 expression seen in myrf depleted
embryos.
To determine if there was a change in furin expression in myrf depleted embryos we
performed WISH. We found that both in gastrulation stages (stage 11 shown in figure 18C) and
early tailbud stages (stage 23 shown in figure 18C), myrf depleted embryos had an increase in
furin mRNA expression compared to control embryos (Fig. 18C). Additionally, Western Blot
showed a 148% increase in furin protein in myrf depleted embryos compared to control, and this
increase in furin protein concentration could not be rescued by co-injection with nMO (Figure
18D). This suggests that although the myrf depletion phenotype can be rescued with nodal1
depletion, furin protein concentration continues to be high in the co-injected embryos. We also
performed a Western Blot to show that there is a loss of furin protein in embryos overexpression
wildtype myrf mRNA whereas overexpression of patient variant constructs does not induce a
loss of furin (Figure 17E), indicating that myrf represses transcription of furin, but the patient
variants are not able to function to repress furin.
Finally, to show that the bilateral pitx2 phenotype seen with myrf depletion is due to an
increase of furin protein in these embryos, we conducted a rescue experiment. Two furin
morpholinos (FMo1/2) were injected simultaneously to target all three mRNA transcripts of furin
[61]. When myrf depleted embryos were co-injected with FMo1/2 (n=64), we show that the coinjected embryos successfully rescued the phenotype and only had 3.1% bilateral pitx2
expression, compared to CR-1 only injected embryos (n=163), which had 23.3% bilateral pitx2
expression (Figure 18F). Together, our data suggests myrf transcriptionally represses furin as
one mechanism in its ability to repress nodal1.
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Figure 18: Furin rescues LR patterning defects in myrf depleted embryos. A) Depletion of
furin using CRISPR results in increased L-Loops. B) Depletion of furin also results in
increased absent pitx2 expression. C) Compared to uninjected control embryos, myrf
depleted embryos have increased expression of furin at both gastrulation and tailbud
stages, indicated by the red arrowheads. D) Loss of myrf results in increased furin protein
concentration, and this increase could not be rescued with nodal depletion. E)
Conversely, overexpression of wildtype MYRF mRNA causes a loss of furin protein
concentration whereas overexpression of patient variant constructs does not lead to a
loss of furin. F) Depletion of furin rescues the bilateral pitx2 expression phenotype seen
in myrf depleted embryos.
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5.0 Discussion
MYRF has recently been studied for its role in the generation and maintenance of myelin
in the CNS, and variants of this gene has been identified in multiple patients with congenital
defects. However, its other functions during early development has not been explored. In this
study, we propose a novel function of MYRF as a transcription factor for proper LR patterning
and cardiac development. Loss of myrf in Xenopus tropicalis was efficiently conducted via
CRISPR and was validated by two methods. Myrf depletion leads to abnormal organ situs, with
predominantly abnormal A-looped hearts. Furthermore, myrf depletion results in abnormal
bilateral pitx2 phenotype, but normal GRP markers. This leads us to believe that in myrf
depleted embryos, the LRO is appropriately specified, and myrf functions upstream of pitx2, but
downstream of coco in the LR signaling cascade. Finally, we performed a rescue experiment
and illustrated that the bilateral pitx2 expression seen in myrf depleted embryos was specific to
the loss of myrf. Together, these findings demonstrate that myrf plays a role in LR patterning
and successfully completes specific aims 1A and 1B.
Because our experiments suggested that myrf acts between pitx2 and coco in the LR
patterning cascade, we hypothesized that myrf functions by affecting nodal signaling. We
successfully showed that depletion of myrf leads to bilateral nodal1 at stage 22, greater intensity
and area of expression of nodal1 on the left side of the embryo at stage 24, and persistent
expression of nodal1 on the left side of the embryo at stage 28. A rescue experiment was
conducted to show that depletion of nodal1 can rescue the bilateral pitx2 phenotype and
increased P-smad2 concentration seen in myrf depleted embryos. At this point, we had three
main hypotheses: 1) myrf functions on the left side of the embryo to maintain nodal1 signaling to
only the left side, 2) myrf acts at the midline to maintain nodal1 signaling to only the left side, or
3) myrf acts on the right side of the embryo to repress nodal1 signaling on the right. A one-oftwo cell experiment showed that depletion of myrf on the left side of the embryo resulted in LR
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patterning defects, but depletion on the right side did not lead to any defects. This result
eliminates hypothesis 3, as myrf is not necessary on the right side of the embryo for proper
organ situs. WISH expression of midline markers showed that myrf does not affect the integrity
of the midline, which eliminated hypothesis 2. Finally, a rescue experiment showed that
depletion of nodal1 on either the left or the right side of myrf depleted embryos rescued the
bilateral pitx2 phenotype, which suggests that loss of myrf leads to an accumulation of nodal1
mRNA, leading to increased auto-transcription of nodal1 on both the left and right sides of the
embryo, thereby perturbing LR patterning. Cumulatively, this provides a plausible mechanism of
how myrf functions in LR patterning at the level of nodal signaling, completing specific aim 1C.
Although it is known that myrf is a transcription factor in the context of myelination, it was
unclear if it also functions in this manner in LR patterning. Through creating three different
mRNA constructs containing a patient mutation located in the DNA binding domain, we showed
that the patient variant constructs did not have a overexpression phenotype and could not
rescue the bilateral pitx2 phenotype in myrf depleted embryos, while wildtype myrf mRNA did
have an overexpression phenotype and could rescue the pitx2 defect. This completed specific
aim 2A and showed that myrf acts as a transcription factor in early development.
Preliminary studies found that loss of myrf not only resulted in abnormal organ situs, but
also caused gastrulation defects. Analysis of gastrulation markers showed defects in paraxial
mesoderm markers myoD and myf5, and more interestingly, increased expression of nodal1. A
rescue experiment showed that the gastrulation defects could be rescued by nodal1 depletion,
completing specific aims 3A and 3B.
Finally, based on previous studies, we hypothesized that myrf inhibits nodal1 through
transcriptionally inhibiting furin. Loss of myrf leads to excessive furin expression, shown both
through WISH and western blot, and overexpression of MYRF leads to loss of furin protein.
Through a rescue experiment, we also illustrated that depletion of furin can rescue the LR
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patterning defects. Therefore, we ultimately propose that myrf transcriptionally represses furin, a
proprotein convertase that functions to convert pro-nodal into its mature, biologically active form.
Our data suggests that depletion of myrf leads to increased furin expression and
increased availability of mature nodal. This is especially important in nodal signaling, as it is
known that nodal positively regulates its own expression in the LPM [35]. While normally this
auto-activation of nodal is what allows for rapid expansion of nodal expression into the lateral
plate, it is then limited to the left side by the midline nodal antagonist lefty. However, we
speculate that the increased expression of furin and likely increased processing of nodal ligand,
a more dramatic expansion of nodal may cause right-sided transcription of nodal, allowing for
abnormal right sided pitx2 expression of nodal in myrf depleted embryos. Co-injection with suboptimal dose of nMO on the left further illustrates how normalizing nodal signaling on the left
results in normal LR patterning. A recently published study conducted in zebrafish also
describes a similar relationship between nodal and furin, where increasing furinA levels in
wildtype embryos resulted in anteriorward expression of spaw as well as increased incidence of
bilateral spaw expression in the LPM [79].
Conversely, we predict that the inability of pro-nodal to be converted to its mature form
would also lead to LR patterning abnormalities, due to loss of normal nodal signaling on the left.
Injection of SPC inhibitors in Xenopus results in strong suppression of left-handed expression of
nodal1, lefty, and pitx2, supporting this theory [80]. Additionally, sequencing of a pediatric
patient with dextro-transposition of the great arteries identified a loss of function mutation within
the SPC cleavage site in NODAL [81]. Interestingly, our data shows that overexpression of
MYRF mRNA in wildtype embryos results in reduced furin protein on Western Blot and
abnormal organ situs, but normal left-handed pitx2 expression. Due to the redundancy in
proprotein convertases, loss of furin alone may not be sufficient to inhibit cleavage of Nodal.
However, loss of furin in mice showed ventral closure defects and lack of axial rotation despite
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appropriately expressed NODAL [57]. Therefore, the loss of furin that results from myrf
overexpression may affect LR patterning and early development in a nodal independent
manner. Further research will better elucidate this mechanism.
Interestingly, the same study that showed SPC inhibitors in Xenopus resulted in
suppression of nodal1 also demonstrated a different result with overexpression of furin. When
overexpressing furin on the left, no effect was observed on LR patterning defects. Instead,
overexpression on the right side led to 100% heart looping reversal and bilateral nodal1 and
pitx2 expression [48]. This is the opposite of what we would predict based on our own data. In
our case, we predict that myrf suppresses furin expression; therefore, depletion of myrf
effectively leads to overexpression of furin. In that context, depletion of myrf on the left, but not
the right led to LR patterning defects. There are many hypotheses that could explain these
differences. myrf may have multiple downstream targets that can modulate nodal, and it is the
cumulative effect of all of its downstream targets that result in the phenotype we observe.
Different myrf targets or cofactors of myrf targets may be differentially expressed on the left and
right sides of the embryo, leading to different downstream read-outs of myrf depletion on the left
and right sides. Additionally, myrf may have nodal-independent effects on LR patterning that
were not studied. ChIP-Seq analysis on whole embryos at gastrulation or tailbud stage may
provide further candidate targets for future analysis, since current ChIP data sets were not
collected during relevant developmental stages.
Studies in mice suggest that stability of Nodal protein is decreased after cleavage,
leading to increased autocrine function, but decreased paracrine signaling [82]. Our data
challenges this theory, as we found depleting myrf leads to excess nodal signaling and bilateral
pitx2 expression, and co-injection of suboptimal dose of nodal MO on the left side rescues LR
patterning. This suggests that in myrf depleted embryos, mature nodal protein is stable enough
to both induce auto-transcription of itself across the midline and induce right-sided pitx2
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expression. It is possible that species differences between Xenopus and mice may explain
these differences. Furthermore, of the six nodal ligands in Xenopus, mature nodal1 may be
more stable than other Xenopus ligands, which may be why a robust bilateral pitx2 phenotype
was seen in myrf depleted embryos.
While MYRF continues to be well studied in the context of generating and regenerating
myelin [18] [83], our study provides a novel function of MYRF in early development. A weakness
to this study is that it is possible that myrf may have multiple target that cumulatively modulate
LR patterning, as discussed earlier. CHIP-Seq analysis on whole embryos at gastrulation or
tailbud stage may provide further candidate targets for future analysis, since current data sets
were not collected during relevant developmental stages. Additionally, an unanswered question
in this study is why there is a defect in myoD and myf5 expression that cannot be rescued with
nodal1 depletion, and more intriguingly why the myf5 defect is asymmetric, as gastrulation
occurs well before the LRO is completely formed and LR asymmetry exists in the embryo.
Further studies may provide not only more knowledge about the function of myrf, but perhaps
about gastrulation as well.
MYRF has been implicated in other congenital defects, which include congenital
diaphragmatic hernia, urogenital abnormalities, and pulmonary hypoplasia, and it would be
intriguing to see if our proposed mechanism also plays a role in these defects. While our study
sheds some light on how MYRF variants lead to congenital defects, further study into the
mechanisms of MYRF function may provide additional answers for patients and their families
with congenital defects.
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